{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T02:45:04Z","timestamp":1776134704620,"version":"3.50.1"},"reference-count":41,"publisher":"Open Exploration Publishing","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Explor Target Antitumor Ther"],"accepted":{"date-parts":[[2026,3,9]]},"abstract":"<jats:p xml:lang=\"en\">Aim: Intravesical Bacillus Calmette\u2013Gu\u00e9rin (BCG) is the standard therapy for non-muscle invasive bladder cancer (NMIBC); however, many patients experience recurrence or progression. We examined how urinary immune signals and the urinary microbiome change across BCG and are related to outcomes. Methods: In this single-center prospective cohort study, adults with NMIBC underwent transurethral resection of bladder tumor (TURBT), followed by BCG induction. Urine was collected before TURBT, before BCG, after BCG induction, and three months later. Urine sediment mRNA (PD-L1, PD-L2, CD33, and CD204) was quantified using TaqMan \u0394Ct. The urinary microbiome was profiled using 16S rRNA gene sequencing, and diversity, composition, and taxon balance were evaluated using nonparametric tests, PERMANOVA, repeated-measures correlations, and mixed-effects models. We analyzed the relationship between the urinary microbiome and prognosis. Results: Twenty-three patients were analyzed; ten recurrences, eight progressions, and three deaths were observed. Relative to baseline, CD33 increased after BCG and after three months; PD-L2 increased immediately after BCG and returned to baseline by three months; PD-L1 and CD204 increased after BCG. Shannon alpha-diversity was unchanged, but total read count was higher at three months, with stable beta-diversity and dispersion. Higher PD-L1 expression was associated with lower Actinobacteria abundance in the bladder cancer microenvironment. A higher post-BCG Firmicutes\/Bacteroidetes ratio was associated with worse prognosis, with the clearest signal for progression-free survival (PFS) observed in the univariate Cox models. Higher post-BCG Corynebacterium and Enterobacteriaceae abundance was associated with better PFS. Conclusions: BCG was associated with higher urinary PD-L1\/PD-L2 and myeloid marker transcripts, while overall community structure remained stable. These exploratory data support that pre-BCG microbial features may be related to early response, and post-BCG profiles may reflect durability and survival. Urine immune-microbiome profiling could be a feasible, noninvasive adjunct for monitoring and risk stratification in NMIBC.<\/jats:p>","DOI":"10.37349\/etat.2026.1002365","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:50:21Z","timestamp":1776131421000},"update-policy":"https:\/\/doi.org\/10.37349\/open_exploration_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes of urinary immunity and microbiome after intravesical BCG therapy and their association with outcomes in NMIBC"],"prefix":"10.37349","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3909-1133","authenticated-orcid":false,"given":"Yuki","family":"Oda","sequence":"first","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9503-7356","authenticated-orcid":false,"given":"Makito","family":"Miyake","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1150-1298","authenticated-orcid":false,"given":"Nobutaka","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Owari","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-9128","authenticated-orcid":false,"given":"Kota","family":"Iida","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-0372","authenticated-orcid":false,"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-7877","authenticated-orcid":false,"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan; Department of Prostate Brachytherapy, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1507-2464","authenticated-orcid":false,"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Nara Medical University, Kashihara 634-8521, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"21850","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.13.04109","article-title":"The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040","volume":"13","author":"Zhang","year":"2023","journal-title":"J Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/s0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","article-title":"Bacillus Calmette-Gu\u00e9rin treatment of non-muscle invasive bladder cancer","volume":"18","author":"Sylvester","year":"2011","journal-title":"Int J Urol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184712","article-title":"Tumor-Associated Macrophages in Bladder Cancer: Biological Role, Impact on Therapeutic Response and Perspectives for Immunotherapy","volume":"13","author":"Leblond","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/cells13211779","article-title":"Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target","volume":"13","author":"Klein","year":"2024","journal-title":"Cells"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/diseases7020044","article-title":"Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Gu\u00e9rin","volume":"7","author":"Miyake","year":"2019","journal-title":"Diseases"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.eururo.2015.02.041","article-title":"\u201cSterile Urine\u201d and the Presence of Bacteria","volume":"68","author":"Wolfe","year":"2015","journal-title":"Eur Urol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.euf.2016.11.001","article-title":"The Urinary Tract Microbiome in Health and Disease","volume":"4","author":"Arag\u00f3n","year":"2018","journal-title":"Eur Urol Focus"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1128\/JCM.02876-13","article-title":"Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder","volume":"52","author":"Hilt","year":"2014","journal-title":"J Clin Microbiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-29054-w","article-title":"The urinary microbiome associated with bladder cancer","volume":"8","author":"Popovi\u0107","year":"2018","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrurol.2014.361","article-title":"The microbiome of the urinary tract\u2014a role beyond infection","volume":"12","author":"Whiteside","year":"2015","journal-title":"Nat Rev Urol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1125809","article-title":"Impact of intravesical Bacillus Calmette-Gu\u00e9rin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer","volume":"13","author":"James","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/ju.0000000000001336","article-title":"The Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage","volume":"205","author":"Oresta","year":"2021","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.617002","article-title":"Urinary Microbiome: Yin and Yang of the Urinary Tract","volume":"11","author":"Perez-Carrasco","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8111715","article-title":"The Influence of Probiotics on the Firmicutes\/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease","volume":"8","author":"Stojanov","year":"2020","journal-title":"Microorganisms"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2908295","article-title":"Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer","volume":"29","author":"Chakra","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1648698","article-title":"Bladder cancer immunotherapy parallel advances in BCG optimization and next-generation vaccine platforms","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2022.100061","article-title":"Potentiation of the therapeutic effect of intravesical BCG through synthetic and biogenic selenium nanoparticles in a nitrosamine-induced bladder cancer mouse model","volume":"6","author":"Ajideh","year":"2022","journal-title":"Adv Cancer Biol - Metastasis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071356","article-title":"PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Therapy","volume":"16","author":"Maas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn4118","article-title":"Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin","volume":"15","author":"de Jong","year":"2023","journal-title":"Sci Transl Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"22.e13","DOI":"10.1016\/j.urolonc.2023.11.003","article-title":"The bladder microbiota is not significantly altered by intravesical BCG therapy","volume":"42","author":"Heidrich","year":"2024","journal-title":"Urol Oncol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-061421","article-title":"Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol","volume":"12","author":"Bieri","year":"2022","journal-title":"BMJ Open"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI184321","article-title":"The gut microbiome and cancer response to immune checkpoint inhibitors","volume":"135","author":"Gazzaniga","year":"2025","journal-title":"J Clin Invest"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.5217\/ir.2023.00019","article-title":"Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review","volume":"21","author":"Hwang","year":"2023","journal-title":"Intest Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100923","article-title":"Checkpoint inhibitor responses can be regulated by the gut microbiota - A systematic review","volume":"43","author":"Zeriouh","year":"2023","journal-title":"Neoplasia"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010144","article-title":"Longitudinal Transcription Profiling of Bladder Cancers Dictate the Response to BCG Treatment and Disease Progression","volume":"25","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05392-5","article-title":"PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG","volume":"43","author":"de Jong","year":"2025","journal-title":"World J Urol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1097\/JU.0000000000001576","article-title":"Intravesical Anti-PD-1 Immune Checkpoint Inhibition Treats Urothelial Bladder Cancer in a Mouse Model","volume":"205","author":"Kirschner","year":"2021","journal-title":"J Urol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/OTT.S165840","article-title":"Bacillus Calmette-Gu\u00e9rin and anti-PD-L1 combination therapy boosts immune response against bladder cancer","volume":"11","author":"Wang","year":"2018","journal-title":"Onco Targets Ther"}],"container-title":["Exploration of Targeted Anti-tumor Therapy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:50:23Z","timestamp":1776131423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.explorationpub.com\/Journals\/etat\/Article\/1002365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":41,"URL":"https:\/\/doi.org\/10.37349\/etat.2026.1002365","archive":["Portico","Portico"],"relation":{},"ISSN":["2692-3114"],"issn-type":[{"value":"2692-3114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"2025-11-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":2,"name":"published","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"1002365"}}